Christopher Yasenchak, MD, on 1st line brentuximab vedotin + nivolumab in Hodgkin’s lymphoma

Acceptable Safety Observed With Frontline Brentuximab Vedotin Combo in HLПодробнее

Dr. Yasenchak on the Safety Profile of Brentuximab Vedotin/Nivolumab in Hodgkin LymphomaПодробнее

Dr. Yasenchak on Brentuximb Vedotin Plus Nivolumab in Hodgkin LymphomaПодробнее

Brentuximab vedotin combined with nivolumab for Hodgkin lymphomaПодробнее

Alex Herrera on Nivolumab/Brentuximab Vedotin Combination for Patients with Hodgkin LymphomaПодробнее

Brentuximab vedotin, nivolumab, doxorubicin & dacarbazine for early stage classical Hodgkin lymphomaПодробнее

SGN35-027: Brentuximab vedotin with nivolumab, doxorubicin, and dacarbazine in HLПодробнее

Christopher Yasenchak, MD, on the most impressive data in the treatment of Hodgkin’s lymphomaПодробнее

Dr. Yasenchak on Brentuximab Vedotin Added to R-CHOP in DLBCLПодробнее

Lymphoma updates: CAR-T, brentuximab & nivolumabПодробнее

Emerging therapeutic options for Hodgkin lymphomaПодробнее

E4412 update: ipi-nivo-brentuximab for R/R Hodgkin lymphomaПодробнее

Updates from the ECHELON-1 studyПодробнее

Brentuximab vedotin-nivolumab alone and then with R-CHP as frontline therapy for PMBCLПодробнее

CheckMate 205: 5 year follow-up of nivolumab in HLПодробнее

472 Consolidation with Nivolumab and Brentuximab VedotinПодробнее

Ipilimumab, nivolumab & brentuximab vedotin for R/R Hodgkin lymphomaПодробнее

NIVAHL: nivolumab and AVD in early-stage unfavorable HLПодробнее

Dr. Rizvi on Brentuximab Vedotin Plus Checkpoint Inhibition in Hodgkin LymphomaПодробнее